The 11 analysts offering 12-month price forecasts for Iovance Biotherapeutics Inc have a median target of 45.00, with a high estimate of 65.00 and a low estimate of 38.00. The median estimate represents a +46.29% increase from the last price of 30.76.
The current consensus among 12 polled investment analysts is to Buy stock in Iovance Biotherapeutics Inc. This rating has held steady since April, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.53
Reporting Date Aug 06
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.